Latest Breaking News On - Msn labs - Page 1 : comparemela.com

HYDERABAD: After Natco Pharma, now another Hyderabad-based pharma company MSN Laboratories Pvt Ltd (MSN) has initiated the process for conducting Phase III clinical trials of anti-viral drug Molnupiravir for treatment of Covid-19 in the country. The study will be conducted on over 2,400 non-hospitalised patients suffering from mild to moderate Covid-19 disease at over 40 sites across the country. The company said the first dosing is expected to begin soon. The company received approval for conducting the clinical trials from the Indian drugs regulator Drugs Controller General of India (DCGI) – on May 19. “Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for Covid treatment. MSN R&D team has developed both the API and Formulation, is expecting to launch soon after the successful conclusion of clinical study followed by regulatory approval,” the company said.

Andhra pradeshEli lillyNatco pharmaLaboratories pvt ltdAfter natco pharmaPvt ltdController generalNdia newsNdia news todayOday newsGoogle newsReaking newsMsn labsDrugs controller generalஆந்திரா பிரதேஷ்எலி லில்லி